26.07.2022 - LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies (PMM) patients with mitochondrial DNA (mtDNA) defects on track to be completed year-end 2022Alignment .
Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer - read this article along with other careers information, tips and advice on BioSpace
IRVINE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic
Take 1 minute to subscribe and you ll get this story immediately, plus:
52 weekly issues
Book of Lists the most comprehensive business resource in San Diego
San Diego 500 influential business leaders you need to know Yours for only $99
First name: